UPTRAVIHCP.COM KEYWORD DENSITY CHECKER

Total words: 2308 | 2-word phrases: 592 | 3-word phrases: 660 | 4-word phrases: 698

PAGE INFO

Title Try to keep the title under 60 characters (61 characters)
Pulmonary Arterial Hypertension (PAH) Treatment Info for HCPs
Description Try to keep the meta description between 50 - 160 characters (158 characters)
Learn about a prescription medication to help treat your patients with pulmonary arterial hypertension (PAH, WHO Group I). See Full Prescribing & Safety Info.
Keywords Meta keywords are not recommended anymore (158 characters)
uptravi, selexipag, actelion, pah, pah treatment, pulmonary arterial hypertension, pulmonary arterial hypertension treatment, prostacyclin pathway targeted therapy, ip receptor agonist, prostacyclin pathway
H1 H1 tag on the page (33 characters)
Before ProgressionTakes More Away

ONE WORD PHRASES 358 Words

# Keyword H1 Title Des Volume Position Suggest Frequency Density
1for308.38%
2pah246.70%
3the195.31%
4of174.75%
5and164.47%
6in154.19%
7uptravi®154.19%
8to143.91%
9patient143.91%
10information143.91%

TWO WORD PHRASES 592 Words

# Keyword H1 Title Des Volume Position Suggest Frequency Density
1uptravi logo81.35%
2patient enrollment81.35%
3for us71.18%
4pulmonary arterial71.18%
5arterial hypertension71.18%
6disease progression61.01%
7prescribing information61.01%
8in pah61.01%
9full prescribing61.01%
10study design50.84%
11actelion pharmaceuticals50.84%
12us inc50.84%
13healthcare professional50.84%
14healthcare professionals50.84%
15information for50.84%
16us healthcare50.84%
17see full40.68%
18online iassist40.68%
19associated with40.68%
20pharmaceuticals us40.68%

THREE WORD PHRASES 660 Words

# Keyword H1 Title Des Volume Position Suggest Frequency Density
1pulmonary arterial hypertension50.76%
2for us healthcare50.76%
3patient enrollment form40.61%
4us healthcare professionals40.61%
5actelion pharmaceuticals us40.61%
6prescribe online iassist40.61%
7pharmaceuticals us inc40.61%
8full prescribing information30.45%
9treatment of pulmonary30.45%
10progression hospitalization safety30.45%
11logo uptravi logo30.45%
12timefromdiagnosis subgroups ctd30.45%
13subgroups ctd subgroup30.45%
14additional analyses realworld30.45%
15see full prescribing30.45%
16hospitalization analysis 7year30.45%
17analysis 7year data30.45%
18action griphon trial30.45%
19dosing start uptravi®30.45%
20start uptravi® uptravi®30.45%
21uptravi® selexipag full30.45%
22iv resources and30.45%
23resources and support30.45%
24and support patient30.45%
25enrollment patient enrollment30.45%
26form prescribe online30.45%
27study design disease30.45%
28of action griphon30.45%
29agonist in pulmonary30.45%
30intended for us30.45%

FOUR WORD PHRASES 698 Words

# Keyword H1 Title Des Volume Position Suggest Frequency Density
1for us healthcare professionals40.57%
2actelion pharmaceuticals us inc40.57%
3dosing start uptravi® uptravi®30.43%
4timefromdiagnosis subgroups ctd subgroup30.43%
5recommendations mechanism of action30.43%
6mechanism of action griphon30.43%
7of action griphon trial30.43%
8uptravi® selexipag full prescribing30.43%
9iv resources and support30.43%
10for patients uptravi logo30.43%
11information for patients uptravi30.43%
12this site is intended30.43%
13agonist in pulmonary arterial30.43%
14form prescribe online iassist30.43%
15of pulmonary arterial hypertension30.43%
16is intended for us30.43%
17hospitalization analysis 7year data30.43%
18for worsening of pah20.29%
19pah parenteral prostanoid or20.29%
20chronic oxygen therapy other20.29%
21of pah parenteral prostanoid20.29%
22prostacyclin pathway therapy in20.29%
23worsening of pah parenteral20.29%
24disease progression event death20.29%
25septostomy for worsening of20.29%
26atrial septostomy for worsening20.29%
27lung transplantation or balloon20.29%
28for lung transplantation or20.29%
29therapy other disease progression20.29%
30need for lung transplantation20.29%
31pah need for lung20.29%
32for pah need for20.29%
33hospitalization for pah need20.29%
34pah disease progression event20.29%
35first pah disease progression20.29%
36oxygen therapy other disease20.29%
37of fc or need20.29%
38other disease progression decrease20.29%
3948 years female 8020.29%
40eraendothelin receptor antagonist fcfunctional20.29%

EXTERNAL LINKS

# URL Whois Check
1https://www.opsumithcp.com/ Whoisopsumithcp.com
2 https://www.tracleer.com/hcp/ Whoistracleer.com
3 https://www.veletri.com/hcp/ Whoisveletri.com
4 https://www.4ventavis.com/hcp_home.html Whois4ventavis.com
5 https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/UPTRAVI-pi.pdf Whoisjanssenlabels.com
6 https://www.uptravi.com Whoisuptravi.com
7 https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/UPTRAVI-pi.pdf Whoisjanssenlabels.com
8 https://www.uptravi.com Whoisuptravi.com
9 https://www.uptravi.com Whoisuptravi.com
10 https://www.opsumithcp.com/ Whoisopsumithcp.com
11 https://www.tracleer.com/hcp/ Whoistracleer.com
12 https://www.veletri.com/hcp/ Whoisveletri.com
13 https://www.4ventavis.com/hcp_home.html Whois4ventavis.com
14 https://www.janssenmsl.com/ Whoisjanssenmsl.com
15 https://www.janssenmsl.com/ Whoisjanssenmsl.com
16 https://www.janssen.com/us/ Whoisjanssen.com
17 https://www.janssen.com/us/ Whoisjanssen.com
18 https://www.uptravi.com Whoisuptravi.com
19 https://www.janssencarepath.com/sites/www.janssencarepath.com/files/uptravi-psmn.pdf Whoisjanssencarepath.com